US20200288762A1 - Intestinal immune-enhancing agent, food product, and medicament - Google Patents

Intestinal immune-enhancing agent, food product, and medicament Download PDF

Info

Publication number
US20200288762A1
US20200288762A1 US16/759,074 US201816759074A US2020288762A1 US 20200288762 A1 US20200288762 A1 US 20200288762A1 US 201816759074 A US201816759074 A US 201816759074A US 2020288762 A1 US2020288762 A1 US 2020288762A1
Authority
US
United States
Prior art keywords
cellulose acetate
iga
substitution
degree
half width
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/759,074
Other languages
English (en)
Inventor
Tadashi Takeuchi
Eiji MIYAUCHI
Shu Shimamoto
Akinobu Matsuyama
Hiroshi Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daicel Corp
Original Assignee
Daicel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daicel Corp filed Critical Daicel Corp
Publication of US20200288762A1 publication Critical patent/US20200288762A1/en
Assigned to DAICEL CORPORATION reassignment DAICEL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MATSUYAMA, AKINOBU, SHIMAMOTO, SHU, MIYAUCHI, Eiji, OHNO, HIROSHI, TAKEUCHI, TADASHI
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/24—Cellulose or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/50—Polysaccharides, gums
    • A23V2250/51—Polysaccharide
    • A23V2250/5108—Cellulose
    • A23V2250/51088—Other cellulose derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to an intestinal immune-enhancing agent, a food product, and a medicament.
  • Immunoglobulins a type of glycoprotein, have classes such as IgA, IgD, IgE, IgG, and IgM. Among these, IgA is present in mammals and avian species. In particular, IgA contained in exocrine fluids, such as saliva, tears, nasal discharge, airway mucus, gastrointestinal secretions, and breast milk is a secretory IgA that serves as the first line of defense of the immune mechanism in protecting the mucosal surface from antigens and microorganisms.
  • exocrine fluids such as saliva, tears, nasal discharge, airway mucus, gastrointestinal secretions, and breast milk is a secretory IgA that serves as the first line of defense of the immune mechanism in protecting the mucosal surface from antigens and microorganisms.
  • the gastrointestinal tract is always in contact with many substances, including antigens and microorganisms, and it is necessary to prevent these antigens and microorganisms from invading the body; specifically, IgA secreted by the intestinal tract is important to mucosal immune functions in preventing bacteria or viruses from adhering to mucosal surfaces and removing foreign substances by capturing foreign antigens and discharging them outside the body. Since promoting IgA secretion in the intestinal tract has promising effects such as enhancing mucosal immune functions and preventing infections or allergies, there is a demand for the development of food products and the like having IgA secretion promoting effect.
  • Non-Patent Literature 1 has the following description (Summary). “The effects of galactooligosaccharides, a type of indigestible oligosaccharide, on the murine immune system were examined. BALB/c mice were housed with free intake of feed containing galactooligosaccharides; 2 weeks after ingestion, the amount of total IgA contained in the feces increased significantly, and then returned to the same level as the control group. Four weeks later, the mice were sacrificed. The galactooligosaccharide group tended to have an increased total IgA of the prepared Peyer's patch cell culture and colon tissue extract.”
  • Non-Patent Literature 2 contains description with the following information (Abstract). Lactosucrose (4G- ⁇ -D-galactosylsucrose, LS) is suggested to be an oligosaccharide for the proliferation of Bifidobacteria in the intestine. Mice were fed with 2% and 5% LS added feed for 4 weeks, and the intestinal mucosal immune responses were determined. In the 2% and 5% LS fed groups, the amounts of IgA in the feces and cecal contents were significantly increased.
  • Patent Document 1 describes that fructooligosaccharides, a type of indigestible oligosaccharides, have been found to enhance IgA and pIgR production in the intestinal mucosa.
  • Patent Document 2 describes significant IgA secretion promoting effect by orally administering resistant dextrins.
  • Patent Document 3 describes a nutritional composition, livestock feed, lipid metabolism improving agent, inflammatory bowel disease and/or immune disorders prophylactic and/or therapeutic agent, cancer prophylactic and/or therapeutic agent, non-alcoholic steatohepatitis prophylactic and/or therapeutic agent, obesity and/or diabetes prophylactic and/or therapeutic agent, and hypercholesterolemia prophylactic and/or therapeutic agent containing a cellulose acetate that has a total degree of acetyl substitution from 0.4 to 1.1.
  • Patent Document 1 JP 2003-201239 A
  • Patent Document 2 JP 2014-152125 A
  • Patent Document 3 WO 2015/146853
  • Non-Patent Literature 1 Sato, et al. Effects of Dietary Galactooligosaccharides on Immune System in Mice. Journal of Japanese Society of Nutrition and Food Science. 2008, Vol. 61, No. 2, p. 79-88.
  • Non-Patent Literature 2 Hino Keiko, et al. Effect of Dietary Lactosucrose (4G-.BETA.-D-Galactosylsucrose) on the Intestinal Immune Functions in Mice. Journal of Applied Glycoscience. 2007, Vol. 54, No. 3, p. 169-172.
  • Non-Patent Literature 1 describes that the ingestion of feed containing a galactooligosaccharide had the tendency to increase the total IgA in, for example, the colon tissue extracts of mice; however, the feed requires a dose containing as much as 5 wt. % of the galactooligosaccharide (the right column of p. 80, Table 2).
  • the total IgA in the feces of the test group that ingested the feed was up to about two times that of the control group and significant difference was observed; however, during the third week of the ingestion of the feed, the total IgA decreased to the same level as that of the control group and was not significantly different (the right column of p. 81, FIG. 1 ). Furthermore, after analysis of the colon tissue extracts and the like, it has been reported that the total IgA had the tendency to increase, but it has been stated that these effects do not have a significant difference (the right column of p. 81, FIGS. 2 and 3 ).
  • Non-Patent Literature 2 describes that while the amount of IgA in the feces of mice was about twice that of the control group one week after the ingestion of feed containing lactosucrose, the amount of IgA decreased greatly after two weeks, and then did not increase greatly ( FIG. 1 ). Particularly, when fed with feed containing 2% of lactosucrose, the amount of IgA decreased greatly after 2 weeks, and then hardly increased ( FIG. 1 ).
  • Patent Document 1 also describes that mice were fed with an experimental feed added with a fructooligosaccharide as much as 5% (w/w). While the IgA antibody content in the feces of 36-day-old mice of the test group fed with the experimental feed was approximately twice that of the control group and was significantly different ( FIG. 5 ), no significant difference was observed from 28-day-old mice and 42-day-old mice in the same experiment ( FIG. 5 ). In addition, while the total IgA antibody content in the colon of the test group among 44-day-old mice was approximately 1.5 times that of the control group ( FIG. 7 ), the amount of IgA antibody per weight of colon tissue was not significantly different ( FIG. 9 ). Furthermore, examination results (FIG.
  • Patent Document 2 also describes that mice were fed with a control feed containing 5 mass% and 7.5 mass% of an indigestible dextrin. Although it has been shown that IgA in the gastrointestinal contents ( FIG. 1 ) and feces ( FIG. 2 ) has increased, the number of mice used in the experiment has not been shown, nor the results of significance test, and some figures did not even include error bars ( FIGS. 1 to 4 ). Furthermore, it can be seen that the figures that include error bars have a large error range, and there was no description regarding the lack of significant difference as a result of the test. Thus, statistical verification has not been performed to determine whether the technique is one that increases IgA in the first place. Also, substrate specificity of IgA has not been examined.
  • Patent Document 3 describes a cellulose acetate that has a total degree of acetyl substitution from 0.4 to 1.1, but there is no mention or suggestion of an intestinal immune-enhancing agent.
  • the object of the present invention is to provide an intestinal immune-enhancing agent that can sufficiently increase IgA in the intestinal tract with a low dose while maintaining an increased amount of IgA for an extended period of time.
  • a first aspect of the present invention relates to an intestinal immune-enhancing agent containing a cellulose acetate that has a total degree of acetyl substitution from 0.4 to 1.1.
  • the cellulose acetate of the intestinal immune-enhancing agent preferably has a compositional distribution index (CDI) of 2.0 or less, the compositional distribution index (CDI) being defined by the equation below.
  • CDI (Measured value of half width of compositional distribution)/(Theoretical value of half width of compositional distribution)
  • Measured value of half width of compositional distribution half width of compositional distribution determined by HPLC analysis of cellulose acetate propionate obtained by propionylation of all residual hydroxyl groups of cellulose acetate (sample).
  • DPw Weight average degree of polymerization (value determined by GPC-light scattering using cellulose acetate propionate obtained by propionylation of all residual hydroxyl groups of cellulose acetate (sample))
  • a second aspect of the present invention relates to a food product containing the intestinal immune-enhancing agent.
  • the content of the cellulose acetate in the food product is preferably 0.1 wt. % or more and less than 5 wt. %.
  • a third aspect of the present invention relates to a medicament containing the intestinal immune-enhancing agent.
  • an intestinal immune-enhancing agent that can sufficiently increase IgA in the intestinal tract with a low dose while maintaining an increased amount of IgA for an extended period of time can be provided.
  • FIG. 1 shows the fecal IgA quantification results of wild-type mice.
  • FIG. 2 shows the quantification results of IgA-coated bacteria in the feces of wild-type mice housed for four weeks.
  • FIG. 3 shows the IgA quantification results at different sites in the intestinal tract of wild-type mice housed for four weeks.
  • FIG. 4 shows the quantification results of IgA-producing plasma cells in the lamina intestinal of the large intestine of wild-type mice housed for four weeks.
  • FIG. 5 shows the quantification results of IgA-coated bacteria in the cecum and feces of monocolonized mice housed for four weeks.
  • the intestinal immune-enhancing agent contains a cellulose acetate that has a total degree of acetyl substitution from 0.4 to 1.1.
  • intestinal tract refers to the small intestine including duodenum, jejunum, ileum, and the like, as well as the large intestine including cecum, proximal colon, distal colon, and the like.
  • immuno-enhancing refers to, for example, increasing IgA, and the increase in IgA includes an increase in IgA-producing plasma cells.
  • the following effects can be achieved: immunoglobulin A (IgA)-producing plasma cells in the intestinal tract (especially the lamina intestinal of the large intestine) increases; IgA in the intestinal tract increases; the increased amount of IgA can be maintained for an extended period of time; and/or the increased antigen-antibody reaction specificity of IgA to bacteria in the phylum
  • IgA immunoglobulin A
  • Proteobacteria reduces bacteria in the phylum
  • Proteobacteria present in the intestinal mucosa is a phylum that includes many pathogenic bacteria such as pathogenic E.
  • the intestinal immune-enhancing agent according to an embodiment of the present disclosure is able to provide such effects even with a lower dose compared to known methods.
  • Total degree of acetyl substitution of cellulose acetate The cellulose acetate according to an embodiment of the present disclosure has a total degree of acetyl substitution (average degree of substitution) from 0.4 to 1.1. When a total degree of acetyl substitution is within this range, solubility in water of the cellulose acetate is excellent; however, when a total degree of acetyl substitution is outside this range, solubility in water of the cellulose acetate tends to decline. It is considered that cellulose acetate is broken down by intestinal bacteria into acetic acid and cellulose in the gastrointestinal tract, and the resulted cellulose is further broken down into short chain fatty acids such as acetic acid via oligosaccharides or monosaccharides.
  • the range of the total degree of acetyl substitution is preferably from 0.5 to 1.0, and more preferably from 0.6 to 0.95.
  • the total degree of acetyl substitution can be measured by a known titration method, in which the degree of substitution of a cellulose acetate is determined after dissolving the cellulose acetate in water. Specifically, the measurement was performed as follows.
  • the total degree of acetyl substitution can be determined by determining a combined acetic acid to a method of measuring an acetyl content prescribed in ASTM D-817-91 (Standard Test Methods of Testing Cellulose Acetate relevant materials) and converting the resulted combined acetic acid into the total degree of acetyl substitution according to the equation below. This is the most common method of determining the degree of substitution of a cellulose acetate.
  • a dried cellulose acetate (sample) is precisely weighed and dissolved in 50 ml of a mixed solvent of ultrapure water and acetone (volume ratio of 4:1); then, 50 ml of a 0.2 N-sodium hydroxide solution is added, followed by saponification at 25° C. for 2 hours. Next, 50 ml of 0.2 N-hydrochloric acid is added, and the amount of acetic acid released is determined by titration with a 0.2 N-sodium hydroxide solution (0.2 N-sodium hydroxide normal solution) using Phenolphthalein as an indicator reagent. In addition, a blank test (test without using sample) is performed in the same manner. Then, the AV (degree of acetylation) (%) is calculated using the equation below.
  • the total degree of acetyl substitution can also be measured by propionylation of hydroxyl groups of a cellulose acetate to obtain a cellulose acetate propionate, dissolving the cellulose acetate propionate in deuterated chloroform, and performing NMR analysis.
  • the propionylation of hydroxyl groups of a cellulose acetate can be performed by a method of complete derivatization of a cellulose acetate described below, in which propionic anhydride is allowed to act upon the cellulose acetate by the catalysis of N,N-dimethylaminopyridine in a pyridine/N,N-dimethylacetamide mixed solvent.
  • CDI Compositional Distribution Index
  • the compositional distribution index (CDI) of the cellulose acetate is not particularly limited.
  • the compositional distribution index (CDI) may be, for example, from 1.0 to 3.0.
  • the compositional distribution index (CDI) is preferably 2.0 or less, more preferably from 1.0 to 2.0, even more preferably from 1.0 to 1.8, even further more preferably from 1.0 to 1.6, and particularly preferably from 1.0 to 1.5.
  • the lower limit of the compositional distribution index (CDI) is 0, which can be achieved by special synthesis techniques such as a technique in which only six positions of a glucose residue are selectively acetylated with a selectivity of 100% while no other position is acetylated; however, such synthesis techniques have not yet been known.
  • the CDI stands at 1.0; however, considerable efforts are required to approach the ideal state described above in actual cellulose reactions.
  • the cellulose acetate when having a uniform compositional distribution, can surely have a water solubility in a wider range of total degree of substitution as compared with conventional equivalents, can be uniformly dissolved, and does not develop a structural viscosity; thus, such cellulose acetate is easy to ingest or administer, breaks down easily, and express the effect of enhanced intestinal immunity easily.
  • compositional distribution index is defined as the ratio of the measured value of half width of compositional distribution to the theoretical value of half width of compositional distribution [(Measured value of half width of compositional distribution)/(Theoretical value of half width of compositional distribution)].
  • the “half width of compositional distribution” is also referred to as “half width of intermolecular substitution degree distribution” or simply “half width of substitution degree distribution”.
  • the evaluation of uniformity of the total degree of acetyl substitution of a cellulose acetate can be performed by using the magnitude of half width of a maximum peak (also referred to as “half-value width”) in an intermolecular substitution degree distribution curve of the cellulose acetate as an index.
  • half width refers to the width of a chart at a height half the peak height (maximum height) in the chart, in which the chart is plotted with the horizontal axis (X-axis) indicating a degree of acetyl substitution and the vertical axis (Y-axis) indicating the abundance at that degree of acetyl substitution; the half width is an index indicating how the distribution disperses.
  • the half width of substitution degree distribution can be determined by high-performance liquid chromatographic (HPLC) analysis. Note that a way to convert the horizontal axis (elution time) in an elution curve of a cellulose ester in HPLC into a degree of substitution (0 to 3) is described in JP 2003-201301 A (paragraphs 0037 to 0040).
  • the theoretical value of half width of compositional distribution (half width of substitution degree distribution) can be calculated stochastically. Specifically, the theoretical value of half width of compositional distribution can be determined according to Equation (1) below.
  • m Total number of hydroxy groups and acetyl groups per molecule of the cellulose acetate
  • Equation (1) The theoretical value of half width of compositional distribution represented by Equation (1) is a half width of compositional distribution, which inevitably occurs when all hydroxy groups in a cellulose are acetylated and deacetylated at the same probability, and which is derived in accordance with the so-called binomial theorem. Furthermore, the theoretical value of half width of compositional distribution, when expressed by the degree of substitution and the degree of polymerization, is expressed as follows. Equation (2) below is defined as a definitional formula to determine the theoretical value of half width of compositional distribution.
  • Equations (1) and (2) should take the degree of polymerization distribution into consideration; in this case, “DPw” in Equations (1) and (2) should be replaced with the function of the degree of polymerization distribution, and the entire equations should be integrated from a degree of polymerization of 0 to infinity.
  • Equations (1) and (2) give a theoretical value with an approximately sufficient precision, as long as they employ Dpw.
  • DPn number average degree of polymerization
  • the “measured value of half width of compositional distribution” refers to a half width of compositional distribution which is obtained by HPLC analysis using a cellulose acetate propionate obtained by propionylation of all residual hydroxy groups (unsubstituted hydroxy groups) of a cellulose acetate (sample).
  • a cellulose acetate having a total degree of acetyl substitution of from 2 to 3 can be subjected to a high performance liquid chromatographic (HPLC) analysis without preprocessing, by which the half width of compositional distribution can be determined.
  • HPLC high performance liquid chromatographic
  • JP 2011-158664 A describes a method of analyzing the compositional distribution of a cellulose acetate having a degree of substitution from 2.27 to 2.56.
  • the measured value of half width of compositional distribution (half width of substitution degree distribution) of the cellulose acetate according to an embodiment of the present disclosure is determined by subjecting residual hydroxy groups in the molecules of the cellulose acetate to derivatization as preprocessing before HPLC analysis, and then subjecting the derivative to the HPLC analysis.
  • the preprocessing is performed in order to convert the cellulose acetate having a low degree of substitution (for example, a cellulose acetate having a total degree of acetyl substitution of 1.1 or less) into a derivative that can be easily dissolved in an organic solvent to enable the HPLC analysis.
  • CAP completely derivatized cellulose acetate propionate
  • CAP completely derivatized cellulose acetate propionate
  • HPLC analysis determines the half width of compositional distribution (measured value).
  • the derivatization should be performed completely so that there are no residual hydroxyl groups in the molecules, and only acetyl and propionyl groups are present. That is, the sum of the total degree of acetyl substitution (DSac) and the total degree of propionyl substitution (DSpr) should be 3.
  • the complete derivatization of a cellulose acetate can be performed by allowing propionic anhydride to act upon the cellulose acetate by the catalysis of N,N-dimethylaminopyridine in a pyridine/N,N-dimethylacetamide mixed solvent. More specifically, the cellulose acetate is subjected to propionylation at a temperature of 100° C.
  • the reaction mixture after the reaction is subjected to precipitation using methanol as the precipitation solvent and yields a completely derivatized cellulose acetate propionate.
  • CAP completely derivatized cellulose acetate propionate
  • the HPLC analysis described above can be performed in the following manner.
  • a plurality of cellulose acetate propionates having different degrees of total acetyl substitution as reference samples are subjected to HPLC analysis using a predetermined measuring apparatus under predetermined measuring conditions, and values of these reference samples measured by the analysis are plotted to give a calibration curve [the calibration curve indicates a relationship between the elution time and the total degree of acetyl substitution (from 0 to 3) of the cellulose acetate propionates and is generally a cubic curve].
  • the half width of compositional distribution (measured value) of the cellulose acetate (sample) can be determined.
  • the HPLC analysis determines the relationship between the elution time and the total degree of acetyl substitution distribution of cellulose acetate propionates. This is the relationship between the elution time and the total degree of acetyl substitution distribution of a substance in which all remaining hydroxy groups in the sample molecules have been converted into propionyloxy groups; therefore, this determination is essentially not different from the determination of the total degree of acetyl substitution distribution of the cellulose acetate according to an embodiment in the present disclosure.
  • HPLC analysis described above is performed under the following conditions.
  • Injection volume 5.0 ⁇ L (sample concentration: 0.1% (wt/vol))
  • a substitution degree distribution curve (also referred to as an “intermolecular substitution degree distribution curve”) is determined from the calibration curve [the substitution degree distribution curve is one of the cellulose acetate propionate, with the vertical axis indicating the abundance of the cellulose acetate propionate and the horizontal axis indicating the total degree of acetyl substitution].
  • a half width of substitution degree distribution is determined by the maximum peak (E) corresponding to the average degree of substitution in the following manner.
  • a base line (A-B) is drawn between a base point (A) at a lower degree of substitution and a base point (B) at a higher degree of substitution of the maximum peak (E) and is tangent to the base point (A) and the base point (B).
  • a perpendicular line is drawn from the maximum peak (E) toward the horizontal axis.
  • An intersection (C) of the perpendicular line and the base line (A-B) is determined.
  • a midpoint (D) between the maximum peak (E) and the intersection (C) is then determined.
  • a line including the midpoint (D) is drawn parallel to the base line (A-B) to determine two intersections (A′ and B′) of the line and the intermolecular substitution degree distribution curve. From the two intersections (A′ and B′), lines perpendicular to the horizontal axis are drawn.
  • the interval between the two X-intercepts of the thus-drawn perpendicular lines is defined as the half width of the maximum peak (namely, the half width of substitution degree distribution).
  • the half width of substitution degree distribution described above reflects that the retention times of cellulose acetate propionate molecule chains contained in the sample vary depending on how much the hydroxyl groups of glucose rings in individual polymer chains constituting the cellulose acetate propionate molecule chains are acetylated. Therefore, the width of the retention time ideally indicates the width of compositional distribution (in the substitution degree unit).
  • HPLC analysis includes a duct that does not contribute to the distribution (such as a guide column for protecting the measuring column). Therefore, the width of retention time often includes an error that is caused not by the width of compositional distribution, but by the configuration of the measuring apparatus.
  • the error is affected typically by the length and inner diameter of the column and by the length and routing of piping from the column to the detector, and varies depending on the configuration of the measuring apparatus, as mentioned above.
  • the half width of substitution degree distribution of the cellulose acetate propionate can be determined as a correction value Z corrected according to a correction formula below.
  • the correction formula can give a more accurate half width of substitution degree distribution as the same (or approximately the same) value not depending on the type of the measuring apparatus and the measuring conditions.
  • X represents the half width of substitution degree distribution (uncorrected value) determined with the predetermined measuring apparatus under predetermined measuring conditions
  • Y (a ⁇ b)x/3+b(0 ⁇ x ⁇ 3)
  • a represents the apparent half width of substitution degree distribution of a cellulose acetate having a total degree of substitution of 3 as determined with the same measuring apparatus under the same measuring conditions as in X described above (this cellulose acetate does not actually have a substitution degree distribution because the total degree of substitution is 3)
  • b represents the apparent height width of substitution degree distribution of a cellulose propionate having a total degree of substitution of 3 as determined with the same measuring apparatus under the same measuring conditions as in X described above
  • x represents the total degree of acetyl substitution of the measurement sample (0 ⁇ x ⁇ 3).
  • cellulose acetate (or cellulose propionate) having a total degree of substitution of 3 refers to a cellulose ester in which all hydroxyl groups of the cellulose are esterified, and actually (ideally) does not have a half width of substitution degree distribution (namely, ideally has a half width of substitution degree distribution of 0).
  • the measured value of the half width of compositional distribution (half width of substitution degree distribution) of the cellulose acetate is preferably from 0.12 to 0.34, more preferably from 0.13 to 0.31, and even more preferably from 0.13 to 0.25.
  • substitution degree distribution gives a stochastically calculated value on the assumption that all acetylation and deacetylation proceed independently and evenly; that is, the formula gives a calculated value according to a binomial distribution. Realistically, however, such ideal situation is unlikely to occur.
  • a cellulose ester has a substitution degree distribution significantly wider than one stochastically determined according to the binomial distribution, unless an special approach is made to allow the hydrolysis reaction of the cellulose acetate to approach the ideal random reaction and/or is made to perform post-processing after the reaction so as to give fractionation in the composition.
  • reaction conditions where deacetylation proceeds at a lower rate for a low-substituted cellulose ester.
  • no specific method to achieve this has yet been known. That is, there is no known special approach to the reaction to control the substitution degree distribution of a cellulose ester so as to be in accordance with the binomial distribution reaction stochastically.
  • a cellulose acetate having a total degree of substitution of 2.3 offers, upon precipitation fractionation, a fractionation depending on the molecular weight and a trivial fractionation accompanied with the degree of substitution (chemical composition). It has not yet been reported that the degree of substitution (chemical composition) as has been found by the present inventors can cause a significant fractionation. In addition, it has not yet been verified that the substitution degree distribution (chemical composition) of a cellulose acetate having a low degree of substitution can be controlled by dissolution fractionation or precipitation fractionation.
  • Another approach found by the present inventors to narrow the substitution degree distribution is a hydrolysis reaction (ripening reaction) of the cellulose acetate performed at a high temperature of 90° C. or above (or higher than 90° C.).
  • the known techniques fail to make detailed analyses and considerations on the degree of polymerization of a product obtained by a high-temperature reaction, but people have believed that cellulose decomposition preferentially occurs in a high-temperature reaction at 90° C. or higher.
  • This view is considered to be an assumption (stereotype) based only on considerations on viscosity.
  • the present inventors have found as follows.
  • the reaction of a cellulose acetate is performed in a large amount of acetic acid at a high temperature of 90° C. or above (or higher than 90° C.), preferably in the presence of a strong acid such as sulfuric acid.
  • a strong acid such as sulfuric acid.
  • the degree of polymerization of the cellulose acetate does not decrease, the viscosity decreases with decreasing CDI. That is, the present inventors have clarified that the decrease in viscosity with the high-temperature reaction is caused not by decrease in degree of polymerization, but by decrease in structural viscosity because of narrowed substitution degree distribution.
  • the product (cellulose acetate having a low degree of substitution) has an extremely low CDI and significantly better solubility in water. This is because not only a forward reaction, but also a reverse reaction occurs upon the hydrolysis. In contrast to this, when the cellulose acetate is hydrolyzed under conditions where reverse reaction is unlikely to occur, the resulting product has a wider substitution degree distribution due to various factors and includes larger contents of cellulose acetates having a total degree of acetyl substitution of less than 0.4 and cellulose acetates having a total degree of acetyl substitution of greater than 1.1, both of which are poorly soluble in water. Thus, the resulting product as a whole has lower solubility in water.
  • the total degrees of acetyl substitution at the 2-, 3-, and 6-positions of the glucose ring of the cellulose acetate can be measured by the NMR method described by Tezuka (Tezuka, Carbonydr. Res. 273, 83 (1995)). That is, free hydroxy groups of a cellulose acetate sample are propionylated with propionic anhydride in pyridine. The resulting sample is dissolved in deuterated chloroform and subjected to 13 C-NMR spectrum measurement.
  • Carbon signals of the acetyl groups appear in the order of the 2-position, 3-position, and 6-position from a higher magnetic field in a region of from 169 ppm to 171 ppm, and carbonyl carbon signals of the propionyl groups appear in the same order in a region of from 172 ppm to 174 ppm.
  • the degrees of acetyl substitution at the 2-, 3-, and 6-positions of the glucose ring of the original cellulose acetate can be determined on the basis of the abundance ratio of acetyl groups and propionyl groups at their corresponding positions.
  • the total degree of acetyl substitution is the “total degree of acetyl substitution”, and the total degree of acetyl substitution can also be determined in the above manner. Note that the total degree of acetyl substitution can be analyzed not only by 13 C-NMR but also by
  • the cellulose acetate preferably has a standard deviation of degrees of acetyl substitution at the 2-, 3-, and 6-positions of the glucose ring of 0.08 or less (from 0 to 0.08).
  • the cellulose acetate when having a standard deviation of 0.08 or less, is approximately evenly substituted at the 2-, 3-, and 6-positions of the glucose ring and is highly soluble in water.
  • the dispersity (polydispersity, Mw/Mn) of the molecular weight distribution refers to a value determined by the GPC-light scattering method using a cellulose acetate propionate obtained by propionylation of all residual hydroxy groups of the cellulose acetate (sample).
  • the cellulose acetate according to an embodiment of the present disclosure preferably has a dispersity (polydispersity, Mw/Mn) of from 1.2 to 2.5.
  • the cellulose acetate when having a dispersity Mw/Mn within the range described above, includes molecules of approximately uniform sizes and is highly soluble in water. It is considered that cellulose acetate is broken down by intestinal bacteria into acetic acid and cellulose in the gastrointestinal tract, and the resulted cellulose is further broken down into short chain fatty acids such as acetic acid via oligosaccharides or monosaccharides.
  • the number average molecular weight (Mn), weight average molecular weight (Mw), and dispersity (polydispersity, Mw/Mn) of the cellulose acetate can be determined by known methods using HPLC.
  • the dispersity (polydispersity, Mw/Mn) of the cellulose acetate can be determined in the following manner.
  • the cellulose acetate (sample) is converted into a completely derivatized cellulose acetate propionate (CAP) by a procedure similar to that in the determination of the measured value of half width of compositional distribution, so as to render a measurement sample soluble in an organic solvent.
  • the completely derivatized cellulose acetate propionate is then analyzed by size exclusion chromatography under the following conditions (GPC-light scattering method).
  • MALLS multi-angle light scattering detector
  • the “weight average degree of polymerization (DPw)” refers to a value determined by the GPC-light scattering method using a cellulose acetate propionate obtained by propionylation of all residual hydroxy groups of the cellulose acetate (sample).
  • the cellulose acetate according to an embodiment of the present disclosure preferably has a weight average degree of polymerization (DPw) of from 50 to 800.
  • the cellulose acetate when having an excessively high weight average degree of polymerization (DPw), tends to have poor solubility in water.
  • the weight average degree of polymerization (DPw) of the cellulose acetate is preferably from 55 to 700, and more preferably from 60 to 600. It is considered that cellulose acetate is broken down by intestinal bacteria into acetic acid and cellulose in the gastrointestinal tract, and the resulted cellulose is further broken down into short chain fatty acids such as acetic acid via oligosaccharides or monosaccharides.
  • the weight average degree of polymerization can be determined in the following manner.
  • the cellulose acetate (sample) is converted into a completely derivatized cellulose acetate propionate (CAP) by a procedure similar to that in the determination of the measured value of half width of compositional distribution.
  • the completely derivatized cellulose acetate propionate is then analyzed by size exclusion chromatography to determine the weight average degree of polymerization (DPw) (GPC-light scattering method), as in the determination of the dispersity (polydispersity, Mw/Mn).
  • the molecular weight (degree of polymerization) and dispersity (polydispersity, Mw/Mn) of a cellulose acetate are measured by the GPC-light scattering method (for example, GPC-MALLS or GPC-LALLS).
  • GPC-MALLS the GPC-light scattering method
  • Mw/Mn the Mw/Mn
  • light scattering detection is generally difficult in an aqueous solvent. This is because an aqueous solvent typically includes a large amount of foreign substances and is prone to secondary contamination even when purified.
  • the aqueous solvent may have unstable spreading of its molecular chain due to ionic dissociation groups present in trace amounts; when a water-soluble inorganic salt (for example, sodium chloride) is added to suppress this, the dissolved state may become unstable, and an aggregate may be formed in the resulting aqueous solution.
  • a water-soluble inorganic salt for example, sodium chloride
  • the cellulose acetate is derivatized so as to be soluble in an organic solvent, and subjected to GPC-light scattering measurement in the organic solvent, because such an organic solvent contains a small amount of foreign substances and is resistant to secondary contamination.
  • the derivatization of the cellulose acetate for this purpose effectively employs propionylation. Specific reaction conditions and post-processing are as described in the determination of the measured value of half width of compositional distribution.
  • the cellulose acetate may be produced, for example, by a hydrolysis step (ripening step) (A), a precipitation step (B), and a washing/neutralizing step (C); in the hydrolysis step (A), a cellulose acetate having a medium to high degree of substitution is hydrolyzed; the washing/neutralizing step (C) may be performed as needed.
  • the total degree of acetyl substitution of cellulose acetate having a medium to high degree of substitution is, for example, from 1.5 to 3, and preferably from 2 to 3.
  • the hydrolysis reaction may be performed by allowing the raw material cellulose acetate to react with water in an organic solvent in the presence of a catalyst (ripening catalyst).
  • a catalyst ripening catalyst
  • the organic solvent include acetic acid, acetone, alcohols (such as methanol), and mixed solvents thereof.
  • a solvent containing at least acetic acid is preferred.
  • a catalyst commonly used as a deacetylation catalyst can be used as the catalyst.
  • Sulfuric acid is particularly preferable as the catalyst.
  • the amount of the organic solvent (for example, acetic acid) used is, for example, from 0.5 to 50 parts by weight, preferably from 1 to 20 parts by weight, and more preferably from 3 to 10 parts by weight, based on 1 part by weight of the raw material cellulose acetate.
  • the amount of the catalyst (for example, sulfuric acid) used is, for example, from 0.005 to 1 parts by weight, preferably from 0.01 to 0.5 parts by weight, and more preferably from 0.02 to 0.3 parts by weight, based on 1 part by weight of the raw material cellulose acetate.
  • the catalyst when used in an excessively small amount, may cause the hydrolysis to require an excessively long time and may thereby cause the target cellulose acetate to have a lower molecular weight.
  • the catalyst when used in an excessively large amount, may cause a larger variation of the depolymerization rate depending on the hydrolysis temperature, thereby causing a high depolymerization rate even at a relatively low hydrolysis temperature, which may impede the production of a cellulose acetate having a certain high level of molecular weight.
  • the amount of water used in the hydrolysis step is, for example, from 0.5 to 20 parts by weight, preferably from 1 to 10 parts by weight, and more preferably from 2 to 7 parts by weight, based on 1 part by weight of the raw material cellulose acetate.
  • the amount of water used is, for example, from 0.1 to 5 parts by weight, preferably from 0.3 to 2 parts by weight, and more preferably from 0.5 to 1.5 parts by weight, based on 1 part by weight of the organic solvent (for example, acetic acid).
  • the water may be present in the whole quantity in the system at the start of the reaction; however, to prevent precipitation of cellulose acetate, a portion of the water to be used may be present in the system at the start of the reaction, with the remaining water being added to the system in one or several batches during the reaction.
  • the reaction temperature in the hydrolysis step is, for example, from 40 to 130° C., preferably from 50 to 120° C., more preferably from 60 to 110° C.
  • the reaction may be performed at a temperature of 90° C. or above (or at a temperature higher than 90° C.).
  • the reaction equilibrium tends to be such that the rate of a reverse reaction (acetylation reaction) relative to a forward reaction (hydrolysis reaction) increases. This narrows the substitution degree distribution and can result in a cellulose acetate having a very low compositional distribution index CDI without specially adjusting the post-processing conditions.
  • a strong acid such as sulfuric acid
  • acetic acid as the reaction solvent
  • a cellulose acetate having a very low compositional distribution index CDI can be obtained by performing precipitation using a mixed solvent including two or more different solvents as a precipitation solvent in the precipitation step, and by performing precipitation fractionation and/or dissolution fractionation in the precipitation step, as described below.
  • the temperature of the reaction system is cooled to room temperature, and the precipitation solvent is added to precipitate the cellulose acetate.
  • An organic solvent miscible with water or an organic solvent having high solubility in water can be used as the precipitation solvent.
  • solvents include ketones such as acetone and methyl ethyl ketone; alcohols such as methanol, ethanol, isopropyl alcohol; esters such as ethyl acetate; nitrogen-containing compounds such as acetonitrile; ethers such as tetrahydrofuran; and mixed solvents thereof.
  • a mixed solvent including two or more solvents is used as the precipitation solvent, the same effects as the precipitation fractionation described below can be obtained, and a cellulose acetate having a narrow compositional distribution (intermolecular substitution degree distribution) and a low compositional distribution index CDI can be obtained.
  • Preferable mixed solvents include, for example, a mixed solvent of acetone and methanol, and a mixed solvent of isopropyl alcohol and methanol.
  • the precipitation fractionation may be performed typically in the following manner.
  • the cellulose acetate (solid) obtained by precipitation is dissolved in water to give an aqueous solution having an appropriate concentration (typically from 2 to 10 wt. %, and preferably from 3 to 8 wt. %).
  • a poor solvent is added to the aqueous solution (or, the aqueous solution is added to the poor solvent), and the mixture is held at an appropriate temperature (typically 30° C. or lower, and preferably 20° C. or lower) to precipitate a cellulose acetate, and the precipitate is collected.
  • the poor solvent include alcohols such as methanol, and ketones such as acetone.
  • the poor solvent may be used in an amount, for example, from 1 to 10 parts by weight, and preferably from 2 to 7 parts by weight, per 1 part by weight of the aqueous solution.
  • the dissolution fractionation may be performed typically in the following manner.
  • the cellulose acetate (solid) obtained by precipitation or the cellulose acetate (solid) obtained by precipitation fractionation is combined with a mixed solvent of water and an organic solvent (for example, ketones such as acetone, alcohols such as ethanol).
  • the mixture is stirred at an appropriate temperature (for example, from 20° C. to 80° C., and preferably from 25° C. to 60° C.) and separated into a dense phase and a dilute phase by centrifugation.
  • the dilute phase is combined with a precipitation solvent (for example, ketones such as acetone, alcohols such as methanol), and the precipitate (solid) is collected.
  • the concentration of the organic solvent in the mixed solvent of the water and the organic solvent is, for example, from 5 to 50 wt. %, and preferably from 10 to 40 wt. %.
  • the precipitate (solid) obtained from the precipitation step (B) is preferably washed with an organic solvent (poor solvent); examples of the organic solvent (poor solvent) include alcohols such as methanol or ketones such as acetone. It is also preferable to wash and neutralize the precipitate with an organic solvent containing a basic substance (for example, alcohols such as methanol, ketones such as acetone). Note that the neutralizing step may be performed immediately after the hydrolysis step; in this case, it is preferable to add the basic substance or an aqueous solution of the basic substance to the hydrolysis reaction bath.
  • an organic solvent poor solvent
  • the neutralizing step may be performed immediately after the hydrolysis step; in this case, it is preferable to add the basic substance or an aqueous solution of the basic substance to the hydrolysis reaction bath.
  • Examples of the basic substance include alkali metal compounds and alkaline earth metal compounds.
  • Specific examples of the alkali metal compounds include: alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; alkali metal carbonates such as sodium carbonate and potassium carbonate; alkali metal hydrogen carbonates such as sodium hydrogen carbonate; alkali metal carboxylates such as sodium acetate and potassium acetate; and sodium alkoxides such as sodium methoxide and sodium ethoxide.
  • alkaline earth metal compounds include: alkaline earth metal hydroxides such as magnesium hydroxide and calcium hydroxide; alkaline earth metal carbonates such as magnesium carbonate and calcium carbonate; alkaline earth metal carboxylates such as magnesium acetate and calcium acetate; and alkaline earth metal alkoxides such as magnesium ethoxide.
  • alkali metal compounds such as potassium acetate are preferred.
  • impurities such as the catalyst (such as sulfuric acid) used in the hydrolysis step can be efficiently removed.
  • the cellulose acetate obtained in the above manner can be pulverized, sorted, or granulated as needed to have a particle size within a certain range.
  • the intestinal immune-enhancing agent according to an embodiment of the present disclosure can be contained in a food product or a medicament; as described below, while a cellulose acetate having an total degree of acetyl substitution from 0.4 to 1.1 alone may be used as a food or a medicament, such cellulose acetate can be used as a component of various food products or medicaments.
  • Examples of a method of ingesting or administering the food product or medicament includes, in particular, oral ingestion or administration.
  • Various forms can be selected.
  • common pharmaceutical forms such as powders, granules, tablets, sugar-coated tablets, capsules, syrups, pills, suspensions, solutions, and emulsions, as well as common food product forms such as beverages; confectionery products such as gum, chocolate, candy, yokan (adzuki-bean jelly), and jelly; noodles; baked products such as bread, cakes, biscuits; canned food products; retort food products; livestock meat food products; fish paste products; edible oil compositions such as margarine, dressings, and mayonnaise; dietary supplements; milk products such as butter, ice cream, yogurt.
  • the food product or medicament according to an embodiment of the present disclosure can be applied not only to humans but also to animals such as domestic animals (bovine, porcine, equine, ovine, etc.), poultry (chickens, ducks, etc.), pets (dogs, cats, monkeys, mice, rats, guinea pigs, etc.).
  • animals such as domestic animals (bovine, porcine, equine, ovine, etc.), poultry (chickens, ducks, etc.), pets (dogs, cats, monkeys, mice, rats, guinea pigs, etc.).
  • intake from 1 g to 10 g per day is preferable for cellulose acetate; sugar-coated tablets, noodles, and baked products such as biscuits are preferred since a relatively large amount can be ingested.
  • the intestinal immune-enhancing agent according to an embodiment of the present disclosure can also be incorporated as a thickening agent to a pharmaceutical form or a food form.
  • the content of a cellulose acetate having a total degree of acetyl substitution from 0.4 to 1.1 in the food product according to an embodiment of the present disclosure is not particularly limited, but is preferably 0.1 wt. % or above in a food product. This is because, by consuming the food product with such content in one day, an effective amount of cellulose acetate can be ingested. From the perspective of sufficiently increasing IgA in the intestinal tract and maintaining the increased amount of IgA for an extended period of time (for example, from 2 to 4 weeks, or 4 weeks and above) without compromising the taste and texture of food, the content of a cellulose acetate having an total degree of acetyl substitution of from 0.4 to 1.1 is preferably from 0.1 wt. % to less than 5 wt. %, more preferably from 1.5 wt. % to less than 3 wt. %.
  • target diseases include infections caused by pathogenic bacteria belonging to the phylum Proteobacteria, such as Salmonella infection, cholera, and Vibrio parahaemolyticus.
  • pathogenic bacteria belonging to the phylum Proteobacteria such as Salmonella infection, cholera, and Vibrio parahaemolyticus.
  • the increase of IgA-producing plasma cells in the intestinal tract, particularly in the lamina intestinal of the large intestine is expected to have effects such as increasing IgA, enhancing mucosal immune function, and preventing infections or allergies.
  • the intake or administration dose of the intestinal immune-enhancing agent may be an amount sufficient to bring about the desired intestinal immune-enhancing effect. Specifically, it can be determined empirically in consideration of: the conditions of the administered individual, such as the individual's age, weight, gender, health conditions, and the state of the stomach, small intestine, and large intestine; the ingestion or administration method; the formulation form, etc.
  • the intake or administration dose per serving may be, for example, from 5 mg/kg body weight to 60 mg/kg body weight, or may be from 10 mg/kg body weight to 40 mg/kg body weight.
  • the number of times of ingestion by or administration to an individual may be once or more than once; when more than once, the administration may be on a regular basis, on an irregular basis, or as needed.
  • the appropriate number of times can be determined empirically in consideration of the conditions of the administered individual, the ingestion or administration method; the formulation form, etc., as with the intake or administration dose.
  • cellulose acetate (trade name “L-70”, available from Daicel Corporation, having a total degree of acetyl substitution of 2.43 and a viscosity at 6% of 145 mPa ⁇ s) was combined with 4.4 parts by weight of acetic acid and 1.9 parts by weight of water, and the mixture was stirred for 3 hours to dissolve the cellulose acetate.
  • the solution was combined with a mixture of 0.58 parts of acetic acid and 0.13 parts by weight of sulfuric acid, and the resulting solution was held at 70° C. to perform hydrolysis. During hydrolysis, water was added to the system in two batches to prevent the precipitation of the cellulose acetate.
  • first hydrolysis step first ripening step
  • second hydrolysis step second aging step
  • third hydrolysis step third ripening step
  • the total degree of acetyl substitution, the weight average degree of polymerization (DPw), the dispersity (polydispersity Mw/Mn), the measured value of half width of compositional distribution, and the compositional distribution index (CDI) of the obtained cellulose acetate were measured by the methods described above.
  • the obtained cellulose acetate has a total degree of acetyl substitution of 0.78, a weight average degree of polymerization (DPw) of 124, a dispersity (polydispersity, Mw/Mn) of 2.0, a measured value of half width of compositional distribution of 0.305, and a compositional distribution index (CDI) of 1.90.
  • AIN-93G Purified feed AIN-93G (REEVE et al. Journal of Nutrition, 123, 1939-1951 (1993)), as well as AIN-93G containing 5 wt. % of cellulose but 2 wt. % of the cellulose is replaced with the cellulose acetate obtained above (hereinafter also referred to as AIN-93G-acetate) were used.
  • mice Male germ-free C57BL/6N mice were housed in an isolator and fed with the K-12 strain ( E. coli ) of E. coli ( Escherichia coli ) to create E. coli monocolonized mice. Also, Bacteroides thetaiotaomicron monocolonized mice were created in the same manner.
  • AID KO mice that is, Activation-induced cytidine deaminase deficient (knockout) mice
  • AID KO mice do not produce IgA.
  • mice used in the experiments described below were housed in the following manner. Eight mice were fed with AIN-93G for 1 week. The feed was freely available. Mice were then grouped into two groups of four individuals each and housed for another 4 weeks. During this 4-week housing, one group was given AIN-93G, which was designated as the Control group. The other group was given AIN-93G-acetate, which was designated as the Acetate group. However, AID KO mice and E. coli monocolonized mice were housed with a different number of individuals, namely, 10 individual mice were grouped into two groups of five individuals each.
  • FIG. 2 Microbiota in the feces of wild-type mice housed for four weeks from the start of administration of AIN-93G or AIN-93G-acetate was stained with PE-labeled anti-IgA antibody (Rat anti-mouse IgA, clone 11-44-2, available from SouthernBiotech) and 4,6-diamino-2-phenylindole (DAPI) and analyzed by flow cytometry to obtain the primary data of flow cytometry. Then, DAPI positive cells stained with DAPI were gated on, of which the IgA positive portions were quantified as IgA-coated bacteria. Flow cytometry was performed using FACS Aria II and the data was analyzed by the software FlowJo (available from Tree Star Inc.). The results are shown in FIG. 2 .
  • FIG. 2A shows the primary data of flow cytometry
  • FIG. 2B shows the percentage (%) of IgA-coated bacteria in DAPI positive cells (% DAPI positive cells).
  • the Acetate group showed a higher value of the percentage (%) of IgA-coated bacteria in DAPI positive cells (% DAPI positive cells) compared to the Control group.
  • IgA-coated bacteria increased as a result of increased IgA with affinity for more bacteria in the Acetate group.
  • the ingestion of cellulose acetate according to an embodiment of the present disclosure is expected to have an immune-enhancing effect, such as protecting the intestinal tract from specific bacteria.
  • Supernatants were obtained by suspending and centrifuging the feces of wild-type mice housed for four weeks from the start of administration of AIN-93G or AIN-93G-acetate with microbiota phosphate buffered saline (PBS).
  • the bacteria contained in the supernatants were stained with IgA-PE antibody (Rat anti-mouse IgA, clone 11-44-2, available from SouthernBiotech) and DAPI; after magnetic cell separation (using products available from Miltenyi Biotec) was performed and IgA negative bacteria were harvested, FACS Aria II was used to harvest IgA positive bacteria. Bacteria were identified by 16S rRNA gene analysis using these samples.
  • Microbiota analysis results of the feces of wild-type mice in the Acetate group housed for 4 weeks are shown in Table 1, and microbiota analysis results of the feces of wild-type mice in the Control group housed for 4 weeks are shown in Table 2.
  • bacteria of the phylum Proteobacteria show significant IgA positivity and higher IgA affinity than bacteria of other phyla, including Actinobacteria, Bacteroidetes, Firmicutes, Tenericutes, and Verrucomicrobia.
  • the phylum Proteobacteria includes bacteria that can be pathogenic, such as Escherichia coli, Salmonella, Vibrio, and Helicobacter.
  • bacteria of the phylum Proteobacteria do not show IgA positivity and do not have high IgA affinity compared to bacteria of other phyla, including Actinobacteria, Bacteroidetes, Firmicutes, Tenericutes, and Verrucomicrobia.
  • IgA concentrations were quantified separately for each site.
  • the quantification method is described as follows.
  • Tissues from the duodenum, jejunum, ileum, cecum, proximal colon, and distal colon of wild-type mice housed for four weeks from the start of administration of AIN-93G or AIN-93G-acetate were harvested, combined with complete EDTA Free Protease Inhibitor Cocktail Tablet (available from Roche), stored in PBS, and then crushed with stainless beads. Protein concentration was measured by BCA protein assay (using products available from Thermo Fisher
  • the tissue IgA concentration of the Acetate group showed a higher value than that of the Control group. In particular, a large increase was observed from the cecum to the colon.
  • the intestinal tissue was sliced into small pieces, combined with RPMI 1640 medium (containing 2% fetal bovine serum (FBS), 400 units/ml (available from Roche Diagnostics Co., Ltd.); collagenase D, 0.25 units/ml dispase (available from Corning); and 0.1 mg/ml DNasel (available from Wako Pure Chemical Industries, Ltd.), and shaken for 30 hours in a water bath at 37° C.
  • RPMI 1640 medium containing 2% fetal bovine serum (FBS), 400 units/ml (available from Roche Diagnostics Co., Ltd.); collagenase D, 0.25 units/ml dispase (available from Corning); and 0.1 mg/ml DNasel (available from Wako Pure Chemical Industries, Ltd.), and shaken for 30 hours in a water bath at 37° C.
  • the digested tissue was washed with RPMI 1640 medium (containing 2% fetal bovine serum (FBS)), resuspended in 10 ml of 35% Percoll (available from GE Healthcare), and layered over 2.5 ml of 70% Percoll in 15 ml of Falcon tubes. Then, the mixture was centrifuged at 2000 rpm for 20 minutes at room temperature, and the cells were separated by a Percoll density gradient. The interface cells were harvested and used as lamina intestinal lymphocytes.
  • RPMI 1640 medium containing 2% fetal bovine serum (FBS)
  • Percoll available from GE Healthcare
  • the isolated lamina limbal lymphocytes were suspended in a staining buffer (PBS, 2% FBS) and stained with IgA-PE antibody (Clone: 11-44-1, available from SouthemBiotech) and B220-APC antibody (Clone:RA3-6B2, available from BioLegend).
  • IgA-PE antibody Clone: 11-44-1, available from SouthemBiotech
  • B220-APC antibody Clone:RA3-6B2, available from BioLegend
  • the lamina limbal lymphocytes thus treated were analyzed by flow cytometry. Those gated and stained with the IgA-PE antibody but not stained with the B220-APC antibody were quantified as IgA-producing plasma cells (IgA+Plasma cells). Also, those stained with both the IgA-PE antibody and the B220-APC antibody were quantified as B cells (IgA+B cells).
  • B cells are a type of lymphocyte, and as they mature and differentiate, they become plasma cells specialized in antibody production. Since one B cell can produce only one type of antibody, a B cell will become activated and start producing antibodies only when a matching antigen or bacterial antigen appears.
  • FIG. 4 shows the primary data of flow cytometry
  • FIG. 4B shows the number of bacteria (absolute cell number) ( ⁇ 10 4 ).
  • the number of IgA-producing plasma cells in the lamina intestinal of the large intestine in the Acetate group was significantly increased as compared to the Control group.
  • an increase in IgA is expected by consuming the cellulose acetate according to an embodiment of the present disclosure.
  • DAPI positive cells stained with DAPI were gated on, of which the IgA positive portions were quantified as IgA-coated bacteria.
  • Flow cytometry was performed using FACS Aria II and the data was analyzed with the software FlowJo (available from Tree Star Inc.).
  • FIG. 5A shows the percentage (%) of the number of IgA-coated bacteria in the DAPI positive cells (% DAPI positive cells) of the cecum (left: Cecal) and feces (right: Fecal) of Bacteroides thetaiotaomicron monocolonized mice.
  • FIG. 5B shows the percentage (%) of the number of IgA-coated bacteria in the DAPI positive cells (% DAPI positive cells) of the cecum (left: Cecal) and feces (right: Fecal) of E. coli monocolonized mice, E. coli being a type of bacteria of the phylum Proteobacteria.
  • the percentage of IgA-coated bacteria in the cecum and feces of Bacteroides thetaiotaomicron monocolonized mice in the Acetate group was reduced as compared to that of the Control group; however, as shown in FIG. 5B , the percentage of IgA-coated bacteria in the cecum and feces of E. coli monocolonized mice in the Acetate group was increased as compared to that of the Control group.
  • IgA in the Acetate group has increased affinity for the K-12 strain of Escherichia coli that belongs to the phylum Proteobacteria.
  • the phylum Proteobacteria includes bacteria that can be pathogenic, such as Escherichia coli, Salmonella, Vibrio, and Helicobacter; thus, it is expected that the intestinal tract is protected from these bacteria by the IgA induced by the cellulose acetate according to an embodiment of the present disclosure (intestinal protection).
  • Microbiota in the colonic lumen contents and colonic mucus layer of wild-type mice housed for four weeks from the start of administration of AIN-93G or AIN-93G-acetate and AID KO mice housed for four weeks from the start of administration of AIN-93G or AIN-93G-acetate were collected using the method described by Gong et al. (FEMS Microbiol Ecol. 2007 Jan; 59(1): 147-57.), and bacteria were identified by 16S rRNA gene analysis.
  • Table 3 shows the results of microbiota analysis of the colonic lumen contents and colonic mucus layer of wild-type mice in the Acetate group housed for 4 weeks
  • Table 4 shows the results of microbiota analysis of the luminal contents and mucus layer of wild-type mice in the Control group housed for 4 weeks
  • Table 5 shows the results of microbiota analysis of the luminal contents and colonic mucus layer of AID KO mice in the Acetate group housed for 4 weeks
  • Table 6 shows the results of microbiota analysis of the luminal contents and colonic mucus layer of AID KO mice in the Acetate group housed for 4 weeks.
  • the wild-type mice in the Acetate group are less susceptible to colonization of bacteria of the phylum Proteobacteria in the mucous layer compared to in the luminal contents, given that the results for microbiota composition were 0.7% in the mucous layer and 2.1% in the luminal contents.
  • the AID KO mice that do not produce IgA, even in the Acetate group, are very susceptible to colonization of bacteria of the phylum Proteobacteria in the mucous layer compared to in the luminal contents, given that the results for microbiota composition were 32.3% in the mucous layer and 1.8% in the luminal contents.
  • the AID KO mice in the Control group are also very susceptible to colonization of bacteria of the phylum Proteobacteria in the mucous layer compared to in the luminal contents, given that the results for microbiota composition were 22.2% in the mucous layer and 1.4% in the luminal contents. From the above, it is considered that the increase in IgA contributed to intestinal protection by leading to a decrease in Proteobacteria in the colonic mucus layer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Data Mining & Analysis (AREA)
  • General Physics & Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Computational Mathematics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Analysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Software Systems (AREA)
  • Probability & Statistics with Applications (AREA)
  • Algebra (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Operations Research (AREA)
  • General Engineering & Computer Science (AREA)
US16/759,074 2017-10-26 2018-10-23 Intestinal immune-enhancing agent, food product, and medicament Abandoned US20200288762A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-207154 2017-10-26
JP2017207154A JP7359374B2 (ja) 2017-10-26 2017-10-26 腸管免疫亢進剤、食品、及び医薬
PCT/JP2018/039373 WO2019082897A1 (fr) 2017-10-26 2018-10-23 Agent favorisant l'immunité intestinale, aliment, et médicament

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/039373 A-371-Of-International WO2019082897A1 (fr) 2017-10-26 2018-10-23 Agent favorisant l'immunité intestinale, aliment, et médicament

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/476,131 Continuation US11896043B2 (en) 2017-10-26 2021-09-15 Intestinal immune-enhancing agent, food product, and medicament

Publications (1)

Publication Number Publication Date
US20200288762A1 true US20200288762A1 (en) 2020-09-17

Family

ID=66246403

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/759,074 Abandoned US20200288762A1 (en) 2017-10-26 2018-10-23 Intestinal immune-enhancing agent, food product, and medicament
US17/476,131 Active 2039-04-16 US11896043B2 (en) 2017-10-26 2021-09-15 Intestinal immune-enhancing agent, food product, and medicament

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/476,131 Active 2039-04-16 US11896043B2 (en) 2017-10-26 2021-09-15 Intestinal immune-enhancing agent, food product, and medicament

Country Status (6)

Country Link
US (2) US20200288762A1 (fr)
EP (1) EP3701955A4 (fr)
JP (1) JP7359374B2 (fr)
KR (2) KR102673932B1 (fr)
CN (2) CN117256858A (fr)
WO (1) WO2019082897A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002154906A (ja) * 2000-11-13 2002-05-28 Michio Hayashi 抗菌剤組成物
JP2003201239A (ja) 2001-11-05 2003-07-18 Meiji Milk Prod Co Ltd 免疫賦活食品組成物
JP4189160B2 (ja) 2001-11-05 2008-12-03 ダイセル化学工業株式会社 セルロースアセテートのアセチル置換度の調整方法
JP4774121B2 (ja) 2010-01-29 2011-09-14 ダイセル化学工業株式会社 位相差フィルム用セルロースジアセテート
JP6160011B2 (ja) * 2013-02-06 2017-07-12 松谷化学工業株式会社 ＩｇＡ分泌促進剤
WO2015146853A1 (fr) * 2014-03-24 2015-10-01 株式会社ダイセル Composition nutritionnelle
JP6212538B2 (ja) 2013-12-20 2017-10-11 株式会社ダイセル 脂質代謝改善作用を有する栄養組成物
CN110548043B (zh) * 2013-12-20 2023-05-12 株式会社大赛璐 炎症性肠疾病和/或免疫异常的改善或预防剂
JP6471068B2 (ja) * 2015-08-24 2019-02-13 株式会社ダイセル 反芻動物用飼料添加剤及び飼料
CN107006718A (zh) * 2017-02-28 2017-08-04 嵊州市派特普科技开发有限公司 禽用提高免疫力复合饲料及其制备方法

Also Published As

Publication number Publication date
US11896043B2 (en) 2024-02-13
CN111565727A (zh) 2020-08-21
EP3701955A4 (fr) 2021-07-21
KR20230074280A (ko) 2023-05-26
CN117256858A (zh) 2023-12-22
JP7359374B2 (ja) 2023-10-11
US20220061372A1 (en) 2022-03-03
WO2019082897A1 (fr) 2019-05-02
JP2019077652A (ja) 2019-05-23
KR20200051016A (ko) 2020-05-12
KR102673932B1 (ko) 2024-06-10
EP3701955A1 (fr) 2020-09-02

Similar Documents

Publication Publication Date Title
Zhou et al. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction
Zha et al. An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis
Villanueva-Millán et al. Gut microbiota: a key player in health and disease. A review focused on obesity
WO2015146853A1 (fr) Composition nutritionnelle
JP2021063079A (ja) グリカン治療剤及びその関連方法
JP6453851B2 (ja) 栄養組成物
Mei et al. Chitin derivatives ameliorate DSS-induced ulcerative colitis by changing gut microbiota and restoring intestinal barrier function
WO2018174141A1 (fr) Agent augmentant les lymphocytes t régulateurs, aliment et médicament
US11896043B2 (en) Intestinal immune-enhancing agent, food product, and medicament
CN114451455A (zh) 改善肠道微环境健康的母乳低聚糖组合物
Zhang et al. Discovery of a novel small molecule with efficacy in protecting against inflammation in vitro and in vivo by enhancing macrophages activation
Fang et al. Effects of Sargassum-derived oligosaccharides, polysaccharides and residues on ameliorating enteritis and dysbiosis in a murine model of food allergy
CN110548043B (zh) 炎症性肠疾病和/或免疫异常的改善或预防剂
Mei et al. Maternal Phlorizin Intake Protects Offspring from Maternal Obesity-Induced Metabolic Disorders in Mice via Targeting Gut Microbiota to Activate the SCFA-GPR43 Pathway
Huang et al. Bergenin Alleviates Ulcerative Colitis By Decreasing Gut Commensal Bacteroides vulgatus-Mediated Elevated Branched-Chain Amino Acids
Issa et al. Long-term exposure from perinatal life to food-grade TiO
Graham et al. The role of fibers and bioactive compounds in gut microbiota composition and health

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: DAICEL CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKEUCHI, TADASHI;MIYAUCHI, EIJI;SHIMAMOTO, SHU;AND OTHERS;SIGNING DATES FROM 20200617 TO 20200805;REEL/FRAME:054051/0634

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION